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Arsenic is widely distributed in nature and is
mainly transported in the environment by
water (1). Chronic exposure of humans to
high concentrations of arsenic in drinking
water is associated with skin lesions (2,3),
peripheral vascular disease (4), hypertension
(5), blackfoot disease (2,6), and a high risk
of cancers (2,7). Inorganic arsenic (iAs) pre-
dominantly exists in two oxidation states
naturally: trivalent arsenite [iAs(III)] and
pentavalent arsenate [iAs(V)]. It is generally
recognized that the toxicity of iAs(III) is a
result of its ability to bind with sulfhydryl
(SH) groups, especially vicinal thiols in pro-
teins, resulting in the dysfunction of enzyme
activity (8), and the toxicity of iAs(V) is a
result of its ability to substitute phosphate in
enzyme-catalyzed reactions, where it can dis-
rupt normal functions of the enzymes
(9,10). It is well known that animal models
are not a good predictor of human carcino-
genesis for arsenic, suggesting that the mech-
anisms for metabolism and toxicity of
arsenic in humans differ from those in ani-
mals. Recent studies suggest that arsenic also
exerts its toxicity through the generation of
reactive oxygen species (ROS) (11–14),
which include hydrogen peroxide and other
chemical forms known as free radicals (e.g.,
superoxide ·O2
–, hydroxyl OH·, and peroxyl
ROO· radicals) (15). iAs(III) has been
shown to enhance the production of heme
oxygenase, an indicator of oxidative stress
(11), and to increase intracellular peroxide
levels in vitro (12,16). Acute and chronic
intake of arsenic increased lipid peroxides
(LPO) in blood, liver, kidney, and other
organs of rats (13,14). However, no infor-
mation has been available on the relationship
between oxidative stress and chronic expo-
sure of humans to arsenic contained in
drinking water. 
In biological systems, a number of
antioxidant defense systems, including enzy-
matic and nonezymatic routes, operate to
control excessive levels of ROS (15).
Superoxide dismutase (SOD), an antioxidase
catalyzing the dismutation of ·O2
– into
hydrogen peroxide and O2, is thought to be
essential for the protection of cells against
ROS and is used experimentally and clini-
cally as an antioxidant drug (17). SOD has
been shown to effectively reduce the fre-
quency of arsenite-induced sister chromatid
exchanges in human peripheral lymphocytes
(18) and XRS-5 X-ray sensitive cells (19).
Glutathione (GSH), the most abundant
nonprotein sulfhydryl (NPSH) in most cells,
acts as a nucleophilic scavenger of numerous
compounds and their metabolites via enzy-
matic and chemical mechanisms and plays
important roles in the protection against
oxidative damage caused by ROS (20–22).
GSH can react nonenzymatically with ROS
or can act as a substrate in the GSH peroxi-
dase-mediated destruction of hydroperoxides
(22). GSH depletion can impair a cell’s
defense against the toxic actions of many
compounds and may lead to cell injury and
death (21,22). Cellular toxicity of arsenic
was found to be inversely related to intracel-
lular GSH levels and thus may be enhanced
by GSH depletion (23). Acute administra-
tion of arsenic to rats produced a signiﬁcant
reduction in hepatic GSH (24). Chronic
exposure of rats or mice to arsenic via injec-
tions caused up to 35% depletion in hepatic
GSH, along with liver injury (13,25).
The purpose of this study was to investi-
gate whether prolonged ingestion of arsenic
contained in drinking water can cause oxida-
tive stress in humans by comparing serum
levels of LPO between the high– and
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Articles
Exposure of experimental animals or cultured cells to arsenic induces oxidative stress, but, to date,
no examination of this phenomenon in humans has been reported. In this study we conducted a
cross-sectional study in Wuyuan, Inner Mongolia, China, to explore the relationship between
chronic arsenic exposure from drinking water and oxidative stress in humans. Thirty-three inhab-
itants who had been drinking tube-well water with high concentrations of inorganic arsenic
(mean value = 0.41 mg/L) for about 18 years constituted the high-exposure group, and 10 resi-
dents who lived nearby but were exposed to much lower concentrations of arsenic in their drink-
ing water (mean value = 0.02 mg/L) were selected as the low-exposure comparison group. Results
of the present study indicated that although the activity for superoxide dismutase (SOD) in blood
did not differ significantly between the two groups, the mean serum level of lipid peroxides
(LPO) was signiﬁcantly higher among the high-exposed compared with the low-exposed group.
Elevated serum LPO concentrations were correlated with blood levels of inorganic arsenic and its
methylated metabolites. In addition, they showed an inverse correlation with nonprotein
sulfhydryl (NPSH) levels in whole blood. The subjects in the high–arsenic-exposure group had
mean blood NPSH levels 57.6% lower than those in the low-exposure group. Blood NPSH levels
were inversely correlated with the concentrations of inorganic arsenic and its methylated metabo-
lites in blood and with the ratio of monomethylarsenic to inorganic arsenic. These results provide
evidence that chronic exposure to arsenic from drinking water in humans results in induction of
oxidative stress, as indicated by the reduction in NPSH and the increase in LPO. Some possible
mechanisms for the arsenic-induced oxidative stress are discussed. Key words: arsenic, chronic
arsenic poisoning, drinking water, glutathione, human, lipid peroxidation, methylation, nonpro-
tein sulfhydryl, oxidative stress. Environ Health Perspect 110:331–336 (2002). [Online
28 February 2002]
http://ehpnet1.niehs.nih.gov/docs/2002/110p331-336pi/abstract.htmllow–arsenic-exposed subjects. We also
sought to elucidate the possible underlying
mechanisms of the oxidative stress induced
by arsenic.
Materials and Methods
Study participants. The present study was
carried out in three villages of Wuyuan, a
town in the southwestern area of Inner
Mongolia, China, where the drinking water
supply system has been dependent on tube
wells with a depth of about 15 m. Thirty-
three volunteer residents (mean age, 42.4 ±
13 years; range, 13–73 years; 21 male and 12
female) from 11 families who lived in the vil-
lages of Yindingtu and Shiba, Wuyuan, were
selected as high–arsenic-exposed subjects. The
tube-well water consumed by this group con-
tained high concentrations of arsenic (0.41 ±
0.11 mg/L, mean ± SD). Ten residents from
ﬁve families who lived in the village of Shahe,
Wuyuan, located 35 kilometers from
Yindingtu and Shiba and with drinking water
containing lower arsenic levels (0.02 ± 0.01
mg/L, mean ± SD), were recruited as control
subjects (mean age, 37.3 ± 16.4 years; range,
23–68 years; 5 male and 5 female). All of the
subjects who were selected in the high– and
low–arsenic-exposed groups are of the Han
nationality. Mean duration of tube-well water
consumption for the high– and low–arsenic-
exposed groups was similar (about 18 years).
Two trained doctors administered a question-
naire during an in-person interview and
obtained information about lifetime drinking
sources, medical history, alcohol consump-
tion, cigarette smoking, and dietary habits.
Two trained dermatologists blinded with
respect to arsenic exposure status conducted
detailed physical examinations. All the sub-
jects who participated in the study provided
informed consent.
Fasting peripheral venous blood was
drawn from the study participants, and the
levels of NPSH and SOD activity in blood
were determined immediately. Serum was
separated immediately from 1.5 mL of blood
and transferred on dry ice to China Medical
University for the measurement of LPO. In
addition, 1.5 mL of each whole blood sam-
ple was transferred on dry ice to St.
Marianna University School of Medicine in
Japan for arsenic measurements. The blood
samples of all study subjects were tested
simultaneously. Water samples were taken
directly from the tube wells and preserved at
room temperature before determination of
arsenic concentrations.
Arsenic analysis. Quantitation of total
arsenic (tAs) in water and iAs, monomethy-
larsenic (MMeAs), and dimethylarsenic
(DMeAs) in blood, urine, and hair was per-
formed as reported previously (26). Brieﬂy,
0.25 g of hair or 0.5 mL of each other sam-
ple was transferred into a 10 mL poly-
methylpentene test tube, and after the
addition of 2 mL 2M sodium hydroxide to
the sample, the mixture was heated at 95°C
for 3 hr. The assay sample was stirred with a
magnetic stirrer once every 30 min. The
treated sample was diluted to make 10 mL,
and an aliquot sample was used for each
assay. iAs and methylated arsenic com-
pounds do not undergo changes in chemical
species (e.g., distribution of methyl groups)
even when heated in 2M NaOH (26). iAs,
MMeAs, and DMeAs were determined by
atomic absorption spectrophotometry
(Shimadzu model AA-6103; Shimadzu,
Kyoto, Japan). Using this method, the detec-
tion limit of each of the three chemical
species of arsenic was 1 ng, and the coeffi-
cient of variation was < 5%.The standard
reference material used was oyster tissue
(No. 1566) from the National Bureau of
Standards (NBS, Washington, DC, USA).
Because of limited seafood ingestion, no
trimethylarsenic was detected in the blood or
urine samples of any subjects. 
Assay of serum LPO. Serum LPO was
determined by measuring the thiobarbitu-
rate-reactive substances (TBA-RS) by the
method of Yagi et al (27). Brieﬂy, serum (300
µL) was mixed with 20% trichloroacetic acid
(2,700 µL) and 0.67% thiobarbituric acid
(1,000 µL) and then incubated at 100°C for
30 min. After cooling with tap water, the
resulting chromogen was extracted with
n-butyl alcohol (4,000 µL) by vigorous shak-
ing. The mixtures were then centrifuged at
3,000 rpm for 10 min, and the supernatants
obtained were monitored at a wavelength of
535 nm by a Shimazu spectrophotometer
(UV-1600; Shimadzu). 1,1,3,3-Tetraethoxy-
propane was used as the external standard, and
the concentration of LPO was expressed as
nanomoles of malondialdehyde equivalents.
Determination of NPSH in whole blood.
We determined whole-blood NPSH levels
using 5,5´-dithiobis-2-nitrobenzoic acid and
measured the absorbance at 412 nm accord-
ing to the method of Ellman (28). Briefly,
whole blood (100 µL) was diluted with 0.4
mL of cold double-distilled water (DDW),
and 0.5 mL of 10% trichloroacetic acid was
added to precipitate the protein. The sample
was mixed well and centrifuged at 15,000
rpm for 5 min. The supernatant was used
for the determination.
Determination of SOD activity in whole
blood. Whole blood (50 µL) was washed
with 5 mL saline and centrifuged at 2,000
rpm for 3 min. The rinsed cells were diluted
with cold DDW to make a ﬁnal volume of
0.2 mL. Ethanol (0.1 mL) and chloroform
(0.1 mL) were mixed with the erythrocyte
lysis to precipitate the hemoglobin. The
tubes were shaken vigorously for 15 min and
centrifuged at 4,000 rpm for 3 min. The
water-ethanol layer was used to determine
SOD activity according to the method of
Elstner and Heupel (29). 
Data analysis. We used SPSS software
(version 6.0; SPSS Inc., Chicago, IL, USA)
to determine statistical significance for the
differences of LPO, NPSH, SOD, and
arsenic levels between the high– and low–
arsenic-exposed groups by independent-sam-
ple t-test. All p values are two tailed.
Results
The concentrations of arsenic in well water
used by the study subjects and the prevalence
of the main clinical manifestations were
described previously (30,31). Table 1 shows
that the mean blood concentrations of iAs,
MMeAs, and DMeAs of the high–arsenic-
exposed group were about 3.0, 9.9, and 5.1
times higher, respectively, than those of the
low–arsenic-exposed group, and the urinary
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Table 1. Levels (mean ± SD) of iAs, MMeAs, and DMeAs in blood and urine and total arsenic in hair of the high– and low–arsenic-exposed subjects.
Blood (µg/L) Urine (µg/L)
Group (n) iAs MMeAs DMeAs iAs MMeAs DMeAs Hair (µg/g)
High (43) 8.2 ± 3.4* 20.7 ± 7.9* 13.2 ± 5.5* 360 ± 173* 468 ± 240* 1,559 ± 529* 1.8 ± 0.8*
Low (10) 2.7 ± 0.9 2.1 ± 0.9 2.6 ± 0.8 71 ± 13 40 ± 22 152 ± 53 0.4 ± 0.2
*Signiﬁcantly different from the low–arsenic-exposure group, p < 0.001. 
Table 2. Comparison of serum LPO concentration, whole blood NPSH level, and SOD activity between the
high– and low–arsenic-exposed groups.
Group (n) LPO (µM)a NPSH (µmol/g Hb)a,b SOD (NU/mL blood)
High (43) 8.8 ± 1.8* 4.3 ± 1.2**  2,654 ± 400
Low (10) 7.1 ± 1.0 7.5 ± 0.5 2,830 ± 99
Abbreviations: Hb, hemoglobin; NU, nitrite unit. Values shown are mean ± SD. 
aSerum level of LPO in ﬁve samples and whole blood NPSH in one sample could not be determined because of limited
sample volume. bData from Pi et al. (30). Signiﬁcantly different from the low–arsenic-exposure group, *p < 0.05; ** p < 0.01 Articles • Arsenic induces oxidative stress in humans
levels of iAs, MMeAs, and DMeAs of the
high–arsenic-exposed group were about 5.1,
11.7, and 10.3 times higher than those of the
low–arsenic-exposed controls. Although our
analytic method did not separate MMeAs(V)
and MMeAs(III), the total MMeAs in blood
(49.2%) was markedly higher than iAs
(19.4%) and DMeAs (31.4%). In contrast,
DMeAs was the most abundant metabolite
in urine (65.3%). The total arsenic in hair of
the high–arsenic-exposed group was 4.5
times higher than that of the low–arsenic-
exposed group. 
Table 2 shows that the mean serum LPO
level of the high–arsenic-exposed group was
signiﬁcantly higher than that of low–arsenic-
exposed controls; conversely, the mean
NPSH level in whole blood of the high–
arsenic-exposed subjects was only 57.3% of
low–arsenic-exposed controls. However, the
SOD activity in whole blood showed no sig-
nificant difference between the high– and
low–arsenic-exposed subjects. 
As shown in Figure 1, the serum LPO
levels were significantly correlated with the
concentrations of iAs, MMeAs, DMeAs, and
total arsenic in blood. In addition, an inverse
correlation of serum LPO concentrations
with NPSH levels in whole blood was
observed, but no correlation was found
between serum LPO concentrations and the
SOD activities in whole blood (Figure 2).
Figure 3 shows that the NPSH levels in whole
blood were correlated with blood concentra-
tions of iAs, MMeAs, DMeAs, and total
arsenic. In addition, the concentrations of
whole-blood NPSH were signiﬁcantly corre-
lated with the ratio of MMeAs to iAs in
blood, which reflects the extent of the first
methylation of iAs in the body (Figure 4), but
were not correlated with the ratio of DMeAs
to MMeAs in urine, which reﬂects the extent
of the second methylation of MMeAs in the
body (p = 0.69; data not shown). 
Discussion
Recently, some areas with chronic arsenic
poisoning were found in Inner Mongolia,
China, where underground water was the
only source of water supply and was com-
monly obtained from tube wells of about
15–30 m in depth. The water sources in
some villages in our study area of Wuyuan
were contaminated with naturally occurring
arsenic. The mean arsenic concentration in
tube-well water from Yindingtu and Shiba,
two of the seriously contaminated villages in
Wuyuan, was 0.41 mg/L, which is about 8.2
and 41 times higher than the limit set for
drinking water in China (0.05 mg/L) and
the present World Health Organization
drinking water guideline value (0.01 mg/L)
(32), respectively. The mean level in the
control village of Shahe was 0.02 mg/L.
Because the groundwater was not used for
irrigation and the surface soil contained
minimal levels of arsenic, arsenic concentra-
tions in wheat, the main farm crop, grown
in both the high-and low-exposure areas
were similar (0.029 vs. 0.024 µg/g, respec-
tively; n = 5). Hence, we can conclude that
the ingestion of tube-well water was the
main exposure source of arsenic in our study
subjects. The main clinical manifestations of
the exposed subjects were similar to those
found in other arsenic poisoning areas of the
world (2,3,33), mainly including cutaneous
depigmentation, hyperpigmentation, and
hyperkeratosis and increased incidence of
peripheral vascular disorder, peripheral neu-
ropathy, and liver swelling (30,31). Both
blood and urine levels of iAs, MMeAs, and
DMeAs were significantly higher in the
high-exposure group compared with the
low-exposure controls. The proportions of
the three metabolites in blood and urine
were different: MMeAs was the main
metabolite in blood (49.2%), whereas
DMeAs was the major metabolite in urine
(65.3%). This difference suggests that part
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Figure 1. Correlation of serum levels of LPO with (A) iAs (r = 0.34; p < 0.05), (B) MMeAs (r = 0.34; p < 0.05),
(C) DMeAs (r = 0.43; p < 0.01), and (D) tAs (r = 0.40; p < 0.05) in whole blood of subjects (n = 38). Serum LPO
in ﬁve samples could not be determined because of limited sample volume. 
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Figure 2. Correlation of serum levels of LPO with whole-blood levels of NPSH (r = 0.60; p < 0.001) and SOD (r =
0.002; p < 0.99) activity in subjects (n = 38). Abbreviations: Hb, hemoglobin; NU, nitrite unit. Serum LPO in ﬁve
samples and whole-blood NPSH in one sample could not be determined because of limited sample volume. 
14
12
10
8
6
4
2
0
21 0 0 1,000
Whole-blood NPSH (µmol/g Hb)
L
P
O
 
i
n
 
s
e
r
u
m
 
(
µ
M
)
L
P
O
 
i
n
 
s
e
r
u
m
 
(
µ
M
)
04 6 8
14
12
10
8
6
4
2
0
Whole-blood SOD (NU/mL blood)
2,000 3,000 4,000of the MMeAs in blood was methylated into
DMeAs before being excreted in the urine.
The present study showed that subjects
chronically exposed to arsenic-contaminated
drinking water in Wuyuan, Inner Mongolia,
had increased serum levels of LPO. This may
be a result of either overproduction of ROS
or accumulation of ROS resulting from dys-
function of antioxidases/antioxidants during
chronic arsenic exposure. Previous works sug-
gested that the toxicity of arsenic compounds
may be mediated by ROS generated during
the metabolism of arsenic compounds
(16,34). Genotoxicity of arsenite (35) and
arsenic-induced apoptosis in NIH3T3 cells
(36), NB4 cells (37), and Chinese hamster
ovary cells (16) were triggered by the genera-
tion of H2O2. ·O2
– and H2O2 were produced
by endothelial cells exposed to low levels of
arsenite (38). DMeAs, a metabolite of iAs,
induced DNA damage via formation of ·O2
–
and dimethylarsenic peroxyl radical (39,40).
8-Hydroxy-2´-deoxyguanosine (8-OhdG),
one of the major ROS-induced DNA base-
modiﬁed products, was detected in the skin of
patients with arsenic-related Bowen’s disease
(41) and in the liver of rats administered
DMeAs (42). Our recent data (43) from ani-
mal experiments revealed that ·O2
–, which
was identified as a Tiron-reactive signal
(Dojindo Lab., Kumamoto, Japan), was gen-
erated in intact aortic rings from rabbits
chronically exposed to 5 mg/L of arsenate in
drinking water for 18 weeks. Also, the levels
of H2O2 in urine were signiﬁcantly higher in
the arsenate-exposed rabbits than in controls.
In the present study, serum LPO concentra-
tions were signiﬁcantly correlated with blood
levels of arsenic and its metabolites, indicating
that the overproduction of ROS induced by
chronic arsenic exposure was one of the main
causes of the elevation of serum LPO observed
in the high–arsenic-exposed subjects.
Arsenic has been reported to produce
·O2– and H2O2 in endothelial cells (38,43).
It is well recognized that SOD can be up-reg-
ulated by overproduction of ROS, and the
lack of expression in SOD knock-out experi-
mental animals results in oxidative stress (44).
SOD can effectively reduce the frequency of
arsenite-induced sister chromatid exchanges
in cells (18,19), suggesting that this antioxi-
dant enzyme contributes to the oxidative
stress-dependent toxicity caused by arsenic. In
the present study, however, the SOD activity
was not significantly altered by chronic
arsenic exposure. The serum LPO levels were
not correlated with the SOD activities in
whole blood. This suggests that the increased
LPO level observed in the high–arsenic-
exposed group was not associated with the
SOD activity in the subjects. The strong
inverse correlation between NPSH and LPO
levels suggests that the depletion of NPSH
was another possible cause of the lipid peroxi-
dation observed in the arsenic-exposed group.
Conversely, the overproduction of ROS could
cause the depletion of NPSH. 
One of the mechanisms by which arseni-
cals produce toxic effects is through their
interaction with cellular sulfhydryl groups in
proteins or elsewhere (45). iAs(III) and
iAs(V) have been shown to react with some
NPSH to form As–SH complexes in vitro at
high concentrations (46,47). However, our
preliminary examination showed that
sulfhydryl groups of dithiols were readily
oxidized by incubation with iAs(III) but not
iAs(V), MMeAs(V), or DMeAs(V), whereas
monothiols were unaffected by all the arseni-
cals (48). In addition, the concentrations of
arsenic in blood of the high–arsenic-exposed
subjects were at the micromolar level, which
is low compared with the level of NPSH in
blood, suggesting that direct binding was
not the main cause of NPSH depletion in
blood. The depletion was signiﬁcantly corre-
lated with the ratio of MMeAs to iAs in
blood, indicating that the first methylation
of iAs would tend to deplete available
NPSH. GSH or other NPSHs, such as
L-cysteine, plays critical roles in the reduc-
tion of As(V) to As(III) in blood and in the
methylation reaction of iAs in liver (49,50). 
Present results suggest that the two main
causes of NPSH depletion were oxidative
reaction with overproduced ROS and the
arsenic methylation process. However,
because GSH is almost always present in all
cells at high concentrations (generally mil-
limolar) (22), the two mechanisms alone do
not seem to explain the striking depletion of
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Figure 3. Correlation of levels of NPSH with (A) iAs (r = 0.41; p < 0.01), (B) MMeAs (r = 0.50; p < 0.001), (C)
DMeAs (r = 0.46; p < 0.001), and tAs (r = 0.51; p < 0.001) in whole blood of subjects (n = 42). Whole-blood
NPSH in one sample could not be determined because of limited sample volume.
Figure 4. Correlation of whole-blood levels of NPSH
with the ratio of MMeAs to iAs in blood (n = 42; r =
0.50; p < 0.001). Whole-blood NPSH in one sample
could not be determined because of limited sample
volume.
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)NPSH in blood. We have reported previ-
ously that chronic exposure to arsenic in
drinking water results in decreased nitric
oxide production in humans (30), and inhi-
bition of NO synthesis leads to a marked
decrease in GSH synthesis through down-
regulation of the rate-limiting enzyme γ-glu-
tamylcysteine synthetase (γ-GCS) in vitro
and in vivo (51,52). NO itself up-regulates
γ-GCS and increases GSH concentration
(53). Our recent work showed that levels of
serum NO metabolites correlated positively
with whole-blood NPSH levels (30).
Therefore, the observed GSH depletion may
be at least in part due to the decreased NO
synthesis caused by chronic arsenic exposure
through down-regulation of γ-GCS.
Furthermore, the oxidation-reduction
cycling of GSH is also central to the cellular
response to oxidative stress. The balance
between the oxidation of GSH to glu-
tathione disulfide (GSSG) and the rapid
reduction of GSSG by GSH reductase con-
tributes to the maintenance of a cellular
GSH:GSSG ratio of about 300:1 (54,55).
Inhibition of GSH reductase diminishes the
intracellular level of GSH. Styblo et al.
(56,57) demonstrated that arsenicals and
arsenothiols, especially methylated trivalent
arsenicals and arsenothiols, were potent
inhibitors of the reduction of GSSG by
GSH reductase. The inhibition constants for
the di(γ-glutamylcyteinylglycinyl)methyl-
dithioarsonite and dicysteinylmethyl-
dithioarsenite, two possible intermediates of
iAs metabolism in vivo, were 0.009 and
0.018 mM, respectively (56,57). Either the
trivalent organoarsenicals generated during
biomethylation of arsenic or the arsenothiols
formed in the cell by reaction with NPSH
could alter the cellular GSH:GSSG ratio,
decreasing the GSH level by the inhibition of
GSH reductase. Recently, the concentrations
of MMeAs(III) and MMeAs(V) in hamster
liver after a single intraperitoneal dose of
iAs(V) (2 mg As/kg of body weight) were 38.5
and 31.4 ng/g, respectively (MMeAs(III)/total
MMeAs = 55.1%) (58). Although the method
we used for determining blood arsenic in the
present study could not separate MMeAs(III)
and MMeAs(V), high levels of total MMeAs
(49.2%) were observed in blood, suggesting
the possibility that high levels of MMeAs(III)
existed in other organs. Interestingly,
MMeAs(III) has been detected in urine after
the administration of sodium 2,3-dimercapto-
1-propane sulfonate to humans chronically
exposed to inorganic arsenic in the drinking
water in Inner Mongolia (59).
In summary (Figure 5), our data provide
evidence that chronic exposure to arsenic from
drinking water in humans results in induction
of oxidative stress, as indicated by the increase
of serum LPO. The oxidative stress induced
by chronic arsenic exposure was associated
with high levels of iAs and its methylated
metabolites in blood, as well as with NPSH
depletion caused by iAs and its methylated
metabolites via different mechanisms. 
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